Effect of Post-Ablational Antiarrhythmic Drugs on Atrial Fibrillation Recurrence: A Systematic Review and Meta-Analysis
DOI:
https://doi.org/10.59958/hsf.7591Keywords:
antiarrhythmic drugs, atrial fibrillation, catheter ablation, recurrence, meta-analysisAbstract
Background: The efficacy of antiarrhythmic drugs in reducing the risk of recurrence of atrial fibrillation (AF) after ablation is still uncertain. Therefore, we conducted a systematic evaluation on post ablation antiarrhythmic drugs (AADs) to reduce the risk of recurrent atrial fibrillation. Methods: The databases of PubMed, Embase, Web of Science (WOS), China Science and Technology Journal (CSTJ) Database, Wanfang Database, China National Knowledge Infrastructure (CNKI), and China Biology Medicine (CBM) were searched from inception to 31 December 2023. Randomized controlled trials (RCTs) investigating the efficacy of AADs in preventing AF recurrence were included. Statistical analysis was performed using Review Manager 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane collaboration, 2014) and Stata18.0 (Stata, College Station, TX, USA). Results: A total of 16 studies, with 3834 patients were included in the final analysis. The use of AADs was found to reduce early risk of recurrence (≤3 months) by 28% (risk ratio (RR) = 0.72, 95% confidence interval (CI): 0.53–0.99, p = 0.04), intermediate risk of recurrence (3–12 months) by 22% (RR = 0.78, 95% CI: 0.67–0.91, p = 0.001), and late risk of recurrence (≥12 months) by 29% (RR = 0.71, 95% CI: 0.47–1.07, p = 0.1). No published bias was detected. In sensitivity analyses, the result is consistent and stable after removal of either study. Conclusions: The use of AADs after ablation can reduce the recurrence of AF, and the effect can last for at least 6 months in the overall population. In subgroup analysis, this protective effect can even last for 12 months in the Asian region. In addition, AADs should be used for at least 3 months after ablation to achieve this protective effect.
References
Wang Z, Chen Z, Wang X, Zhang L, Li S, Tian Y, et al. The Disease Burden of Atrial Fibrillation in China from a National Cross-sectional Survey. The American Journal of Cardiology. 2018; 122: 793–798.
Yu B, Akushevich I, Yashkin AP, Kravchenko J. Epidemiology of Geographic Disparities of Myocardial Infarction Among Older Adults in the United States: Analysis of 2000-2017 Medicare Data. Frontiers in Cardiovascular Medicine. 2021; 8: 707102.
Chiang CE, Okumura K, Zhang S, Chao TF, Siu CW, Wei Lim T, et al. 2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. Journal of Arrhythmia. 2017; 33: 345–367.
Turagam MK, Musikantow D, WhangW, Koruth JS, Miller MA, Langan MN, et al. Assessment of Catheter Ablation or Antiarrhythmic Drugs for First-line Therapy of Atrial Fibrillation: A Meta-analysis of Randomized Clinical Trials. JAMA Cardiology. 2021; 6: 697–705.
Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch KN, Monahan KH, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial [published correction appears in JAMA. 2019; 321: 2370]. JAMA. 2019; 321: 1275–1285.
Ravens U, Odening KE. Atrial fibrillation: Therapeutic potential of atrial K+ channel blockers. Pharmacology & Therapeutics. 2017; 176: 13–21.
Ad N, Holmes SD, Shuman DJ, Pritchard G, Miller CE. Amiodarone after surgical ablation for atrial fibrillation: Is it really necessary? A prospective randomized controlled trial. The Journal of Thoracic and Cardiovascular Surgery. 2016; 151: 798–803.
Boriani G, Mei DA, Imberti JF. Antiarrhythmic drugs in the era of atrial fibrillation ablation. Europace. 2024; 26: euae122.
Bray JJ, Warraich M, Whitfield MG, Peter CU, Baral R, Ahmad M, et al. Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation. The Cochrane Database of Systematic Reviews. 2023; 3: CD013765.
Kanagaratnam P, McCready J, Tayebjee M, Shepherd E, Sasikaran T, Todd D, et al. Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial. Europace. 2023; 25: 863–872.
Gao Y, Zhang K, Xi H, Cai A, Wu X, Cui J, et al. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis. Oncotarget. 2017; 8: 6330–6340.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998; 352: 609–613.
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical Research Ed.). 2011; 343: d5928.
Wang H, Liu J, Liu K, Liu Y, Wang Z, Lou Y, et al. β1-adrenoceptor gene Arg389Gly polymorphism and essential hypertension risk in general population: a meta-analysis. Molecular Biology Reports. 2013; 40: 4055–4063.
Chen J, Ye H. Prevention effect of early application of amiodarone after radiofrequency catheter ablation on recurrence in patients with atrial fibrillation. Chinese Journal of Clinical Rational Drug Use. 2022; 15: 12–20. (In Chinese)
Chen Z, He C, Zhou F. The Effects of Prognosis on Antiarrhythmic Drugs after Radiofrequency Ablation in Patients with Atrial Fibrillation. Chinese and Foreign Medical Research. 2019; 17: 22–24. (In Chinese)
Wang B, Zhang Y, Wang H. Clinical effect of dronedarone combined with radiofrequency ablation on paroxysmal atrial fibrillation. Shanxi Medical Journal. 2022; 51: 995–998. (In Chinese)
Zhang F, Xia Z, Feng L, Wang X. Research of influence by amiodarone applied after paroxysmal atrial fibrillation radiofrequency ablation on recurrence rate. China Practical Medical. 2016; 11: 10–11. (In Chinese)
Zhao Y. Effect of amiodarone on the recurrence of paroxysmal atrial fibrillation after radiofrequency catheter ablation. Chinese Journal of New Clinical Medicine. 2016; 9: 491–494. (In Chinese)
Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, et al. Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). European Heart Journal. 2014; 35: 3356–3364.
Hayashi M, Miyauchi Y, Iwasaki YK, Yodogawa K, Tsuboi I, Uetake S, et al. Three-month lower-dose flecainide after catheter ablation of atrial fibrillation. Europace. 2014; 16: 1160–1167.
Kettering K, Gramley F. Catheter ablation of persistent atrial fibrillation: Beneficial effect of a short-term adjunctive amiodarone therapy on the long-term outcome. Herzschrittmachertherapie & Elektrophysiologie. 2018; 29: 133–140.
Lodziński P, Kiliszek M, Koźluk E, Piątkowska A, Balsam P, Kochanowski J, et al. Does a blanking period after pulmonary vein isolation impact long-term results? Results after 55 months of follow-up. Cardiology Journal. 2014; 21: 384–391.
Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, et al. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). Circulation. 2009; 120: 1036–1040.
Turco P, De Simone A, La Rocca V, Iuliano A, Capuano V, Astarita C, et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation [published correction appears in Pacing and Clinical Electrophysiology. 2007; 30: 1424]. Pacing and Clinical Electrophysiology. 2007; 30: S112–S115.
Mohanty S, Di Biase L, Mohanty P, Trivedi C, Santangeli P, Bai R, et al. Effect of periprocedural amiodarone on procedure outcome in patients with longstanding persistent atrial fibrillation undergoing extended pulmonary vein antrum isolation: results from a randomized study (SPECULATE) [published correction appears in Heart Rhythm. 2015; 12: 1100]. Heart Rhythm. 2015; 12: 477–483.
Leong-Sit P, Roux JF, Zado E, Callans DJ, Garcia F, Lin D, et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circulation. Arrhythmia and Electrophysiology. 2011; 4: 11–14.
Wu G, Jiang H, Huang CX, Yang B, Huang H, Wang YL, et al. Effects of antiarrhythmic drug use on atrial fibrillation recurrence in atrial fibrillation patients post circumferential pulmonary vein ablation. Zhonghua Xin Xue Guan Bing Za Zhi. 2008; 36: 623–626. (In Chinese)
Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al. Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial. European Heart Journal. 2016; 37: 610–618.
Duytschaever M, Demolder A, Phlips T, Sarkozy A, El Haddad M, Taghji P, et al. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. European Heart Journal. 2018; 39: 1429–1437.
Xu B, Peng F, Tang W, Du Y, Guo H. Short-term Antiarrhythmic Drugs After Catheter Ablation for Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. The Annals of Pharmacotherapy. 2016; 50: 697–705.
Chen W, Liu H, Ling Z, Xu Y, Fan J, Du H, et al. Efficacy of Short-Term Antiarrhythmic Drugs Use after Catheter Ablation of Atrial Fibrillation-A Systematic Review with Meta-Analyses and Trial Sequential Analyses of Randomized Controlled Trials. PLoS ONE. 2016; 11: e0156121.
Masuda M, Matsuda Y, Uematsu H, Sugino A, Ooka H, Kudo S, et al. Clinical impact of left atrial remodeling pattern in patients with atrial fibrillation: Comparison of volumetric, electrical, and combined remodeling. Journal of Cardiovascular Electrophysiology. 2024; 35: 171–181.
Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019; 105: 1860–1867.
Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Moretz K, et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. American Heart Journal. 2018; 199: 192–199.
